Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 August, 2017 10:57 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Dr Reddy's to get up to USD 32.5 mn in milestone payments for DFD-06 - 22-Aug-2017 10:33
Eros International Media's promoter completes sale of 11.8 mn shares - 22-Aug-2017 10:22
ONGC receives nod to acquire government's 51.11% stake in HPCL - 22-Aug-2017 10:19
ONGC receives nod to acquire government's 51.11% stake in HPCL - 22-Aug-2017 10:19
HCL Infosystems to distribute Apple products in Indian market - 22-Aug-2017 10:05
Lupin receives EIR from USFDA for Aurangabad facility - 22-Aug-2017 10:02
McNally Bharat bags order worth Rs 5.14 bn - 22-Aug-2017 09:58
TCS' arm to deploy digital learning platform for ICSI - 21-Aug-2017 16:09
Jubilant receives NDA approval for Drax Exametazime - 21-Aug-2017 15:07
Tata Power launches electric vehicle charging infrastructure in Mumbai - 21-Aug-2017 13:54
Blue Star wins multiple MEP orders of over Rs 5 bn - 21-Aug-2017 12:03
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer